Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 593

Results For "C"

9538 News Found

Merck KGaA posts higher earnings, profits across business segments
News | August 04, 2022

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million


Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery
Digitisation | August 04, 2022

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded


Poly Medicure Q1FY23 consolidated PAT drops to Rs. 26.96 Cr
News | August 04, 2022

Poly Medicure Q1FY23 consolidated PAT drops to Rs. 26.96 Cr

The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.


Sandu Pharmaceuticals launches Sandu Kumarvin
News | August 04, 2022

Sandu Pharmaceuticals launches Sandu Kumarvin

Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.


Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
Clinical Trials | August 04, 2022

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.


LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
Drug Approval | August 04, 2022

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients


Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr
News | August 03, 2022

Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr

The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.


Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr
News | August 03, 2022

Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr

The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.


Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma
News | August 03, 2022

Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma

The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.


PIB: Budget allocation and utilization of funds under National Ayush Mission
Policy | August 03, 2022

PIB: Budget allocation and utilization of funds under National Ayush Mission

The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.